Baird served as a co-manager on this transaction.
AboutSynageva BioPharma Corp. (“Synageva” or the “Company”) (NASDAQ-GS: GEVA) recently completed a follow-on offering of 3,000,000 shares of common stock at a price of $98.19 per share, generating gross proceeds of $282.6 million. The Company intends to use the net proceeds from the offering to fund the global launch of Kanuma, expanding global awareness and commercial and manufacturing efforts, expanding infrastructure, including commercial and manufacturing to benefit Kanuma and the rest of pipeline, supporting the initiation of the Phase 1/2 clinical trial for SBC-103, accelerating early-stage programs into the clinic, including SBC-105 and potentially one additional program by the end of 2016, and leveraging proprietary platform to initiate and accelerate multiple new pipeline programs to expand beyond the current opportunity set.
Synageva is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with rare diseases. The company’s pipeline programs consist of protein therapeutics for rare diseases with unmet medical need at various stages of development including the lead program, Kanuma™ (sebelipase alfa) for lysosomal acid lipase deficiency (LAL Deficiency), SBC-103 for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome), and SBC-105 for generalized arterial calcification of infancy (GACI) and other rare calcification diseases. In addition, the company has additional protein therapeutic programs for other rare diseases that are currently at different stages of preclinical development, including potentially bio-superior programs. Synageva is headquartered in Lexington, Massachusetts.
For additional information about this transaction, please contact:
- January 2015
- Synageva BioPharma Corp.
- Target Location
- North America